598020login-checkNew ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients |
DECEMBER, 21, 2022
ISHLT Guidelines Recommend Earlier Use of AlloMap Heart Starting 2 Months Post-Transplant Based on Strength of Clinical Studies
ISHLT Guidelines Recommend Remote Use of GEP and dd-cfDNA Heart Transplant Surveillance, as in HeartCare, May be Used to Reduce the Need for Biopsies and Hospital Visits
BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the International Society for Heart and Lung Transplantation (ISHLT) supporting the use of CareDx’s non-invasive molecular surveillance portfolio. Read the complete press release on CareDx.com.
598020login-checkNew ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients |